A share price of Iterum Therapeutics Plc [ITRM] is currently trading at $0.36, up 3.68%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ITRM shares have gain 12.73% over the last week, with a monthly amount glided 1.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Iterum Therapeutics Plc [NASDAQ: ITRM] stock has seen the most recent analyst activity on May 28, 2021, when Gabelli & Co upgraded its rating to a Hold. Previously, H.C. Wainwright upgraded its rating to Buy on March 15, 2021, and kept the price target unchanged to $2.50. On June 02, 2020, downgrade downgraded it’s rating to Sector Perform and revised its price target to $2 on the stock. Gabelli & Co downgraded its rating to a Sell. SVB Leerink downgraded its rating to a Mkt Perform. H.C. Wainwright started tracking with a Buy rating for this stock on June 21, 2019, and assigned it a price target of $17.
Iterum Therapeutics Plc experienced fluctuations in its stock price throughout the past year between $0.26 and $1.75. Iterum Therapeutics Plc [NASDAQ: ITRM] shares were valued at $0.36 at the most recent close of the market.
Analyzing the ITRM fundamentals
Gross Profit Margin for this corporation currently stands at -1.71% with Operating Profit Margin at -52.03%, Pretax Profit Margin comes in at -68.42%, and Net Profit Margin reading is -69.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is 6.02 and Total Capital is -0.78. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-4.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Iterum Therapeutics Plc [NASDAQ:ITRM] is 2.13. Further, the Quick Ratio stands at 1.96, while the Cash Ratio is 1.71. Considering the valuation of this stock, the price to sales ratio is 49.18.
Transactions by insiders
Recent insider trading involved Dunne Michael W., Director, that happened on Nov 18 ’25 when 6000.0 shares were purchased. Director, Dunne Michael W. completed a deal on Aug 08 ’25 to buy 15000.0 shares.
